DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cytarabine (Cytarabine) - Pancytopenia - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Pancytopenia (81)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cytarabine where reactions include pancytopenia. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 81   Next >>

Possible Cytarabine side effects in 29 year old female

Reported by a health professional (non-physician/pharmacist) from Hungary on 2012-08-24

Patient: 29 year old female

Reactions: Histiocytosis Haematophagic, Neoplasm Malignant, Cytomegalovirus Infection, Pancytopenia, Immunosuppression

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Indication: Hodgkin's Disease
    Start date: 2006-01-01

Carboplatin
    Indication: Hodgkin's Disease

Cisplatin
    Indication: Hodgkin's Disease
    Start date: 2006-01-01

Cytarabine
    Indication: Hodgkin's Disease
    Start date: 2006-01-01

Dacarbazine
    Indication: Hodgkin's Disease
    Start date: 2006-01-01

Doxorubicin Hydrochloride
    Indication: Hodgkin's Disease
    Start date: 2006-01-01

Etoposide
    Indication: Hodgkin's Disease

Gemcitabine Hydrochloride
    Indication: Hodgkin's Disease

Ifosfamide
    Indication: Hodgkin's Disease

Rituximab
    Indication: Hodgkin's Disease

Vinblastine Sulfate
    Indication: Hodgkin's Disease
    Start date: 2006-01-01

Vinorelbine
    Indication: Hodgkin's Disease

Other drugs received by patient: Dexamethasone



Possible Cytarabine side effects in male

Reported by a physician from Germany on 2012-08-24

Patient: male, weighing 95.8 kg (210.8 pounds)

Reactions: Abdominal Pain, Hypotension, Pancytopenia, Ascites, Faecaloma, Diarrhoea, Sepsis, Colitis, Septic Shock

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Clofarabine
    Dosage: 25 mg/m2, unk
    Start date: 2012-07-31
    End date: 2012-08-04

Clofarabine
    Dosage: 25 mg/m2, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-29
    End date: 2012-07-03

Cytarabine
    Dosage: 750 mg/m2, unk
    Start date: 2012-07-31
    End date: 2012-08-04

Cytarabine
    Dosage: 750 mg/m2, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-29
    End date: 2012-07-03

Idarubicin HCL
    Dosage: 7.5 mg/m2, unk
    Start date: 2012-07-31
    End date: 2012-08-02

Idarubicin HCL
    Dosage: 7.5 mg/m2, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-29
    End date: 2012-07-01

Other drugs received by patient: Vancomycin; Metronidazole; Piritramide; Enoxaparin Sodium; Zofran; Clonazepam; Sodium Chloride; Ciprofloxacin; Acyclovir; Ringer; Levothyroxine Sodium; Potassium Chloride; Ceftazidime; Noxafil



Possible Cytarabine side effects in 29 year old female

Reported by a physician from Hungary on 2012-08-23

Patient: 29 year old female

Reactions: Histiocytosis Haematophagic, Pancytopenia, Cytomegalovirus Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Carboplatin
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Cisplatin
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Cytarabine
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Dacarbazine
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Dexamethasone
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Doxorubicin Hydrochloride
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Etoposide
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Etoposide
    Start date: 2007-01-01

Gemcitabine Hydrochloride
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2007-01-01

Ifosfamide
    Start date: 2007-01-01

Ifosfamide
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Rituximab
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2007-01-01

Vinblastine Sulfate
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Vinorelbine
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2007-01-01



Possible Cytarabine side effects in 29 year old female

Reported by a physician from Hungary on 2012-08-23

Patient: 29 year old female

Reactions: Histiocytosis Haematophagic, Pancytopenia, Cytomegalovirus Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Carboplatin
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Cisplatin
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Cytarabine
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Dacarbazine
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Dexamethasone
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Doxorubicin Hydrochloride
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Etoposide
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Etoposide
    Start date: 2007-01-01

Gemcitabine Hydrochloride
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2007-01-01

Ifosfamide
    Start date: 2007-01-01

Ifosfamide
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Rituximab
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2007-01-01

Vinblastine Sulfate
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2006-01-01

Vinorelbine
    Indication: non-Hodgkin's Lymphoma Stage IV
    Start date: 2007-01-01



Possible Cytarabine side effects in male

Reported by a physician from France on 2012-08-17

Patient: male, weighing 80.0 kg (176.0 pounds)

Reactions: Pancytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 2050 mg, qd, days 8-10
    Start date: 2012-04-26
    End date: 2012-04-28

Cytarabine
    Dosage: 1050 mg, qd, days 1-3
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-04-19
    End date: 2012-04-21

Daunorubicin HCL
    Dosage: 125 mg, qd, days 1-3
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-04-19
    End date: 2012-04-21

Granocyte
    Dosage: 410 mcg, qd, days 1-10
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-04-19
    End date: 2012-04-28

Mozobil
    Dosage: 240 mcg/kg, qd, days 1-3
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-04-19
    End date: 2012-04-21

Mozobil
    Dosage: 240 mcg/kg, qd, days 8-10
    Start date: 2012-04-26
    End date: 2012-04-28

Mozobil



Possible Cytarabine side effects in 29 year old female

Reported by a health professional (non-physician/pharmacist) from Hungary on 2012-08-14

Patient: 29 year old female

Reactions: Histiocytosis Haematophagic, Oophoritis, Cytomegalovirus Infection, Pancytopenia, Pyrexia, Pneumonia Cytomegaloviral

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Bleomycin Sulfate
    Indication: Hodgkin's Disease

Carboplatin
    Indication: Hodgkin's Disease

Cisplatin
    Indication: Hodgkin's Disease

Cytarabine
    Indication: Hodgkin's Disease

Dacarbazine
    Indication: Hodgkin's Disease

Dexamethasone
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Gemcitabine Hydrochloride
    Indication: Hodgkin's Disease

Ifosfamide
    Indication: Hodgkin's Disease

Rituximab
    Indication: Hodgkin's Disease

Vinblastine Sulfate
    Indication: Hodgkin's Disease

Vinorelbine
    Indication: Hodgkin's Disease

Other drugs received by patient: Radiotherapy



Possible Cytarabine side effects in female

Reported by a physician from Netherlands on 2012-08-14

Patient: female, weighing 61.9 kg (136.2 pounds)

Reactions: Pancytopenia, Ascites

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Clofarabine
    Dosage: 17 mg at day 2, 4, 6, 8, 10, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-07-01
    End date: 2012-07-09

Cytarabine

Cytarabine
    Dosage: 170 mg, 1 in 1 day
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-30
    End date: 2012-07-09

Idarubicin HCL
    Dosage: 17 mg at day 1, 3, 5
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-30
    End date: 2012-07-04



Possible Cytarabine side effects in 29 year old female

Reported by a health professional (non-physician/pharmacist) from Hungary on 2012-08-14

Patient: 29 year old female

Reactions: Histiocytosis Haematophagic, Oophoritis, Pancytopenia, Cytomegalovirus Infection, Pyrexia, Pneumonia Cytomegaloviral

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Bleomycin Sulfate
    Indication: Hodgkin's Disease

Carboplatin
    Indication: Hodgkin's Disease

Cisplatin
    Indication: Hodgkin's Disease

Cytarabine
    Indication: Hodgkin's Disease

Dacarbazine
    Indication: Hodgkin's Disease

Dexamethasone
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Indication: Hodgkin's Disease

Etoposide
    Indication: Hodgkin's Disease

Gemcitabine Hydrochloride
    Indication: Hodgkin's Disease

Ifosfamide
    Indication: Hodgkin's Disease

Rituximab
    Indication: Hodgkin's Disease

Vinblastine Sulfate
    Indication: Hodgkin's Disease

Vinorelbine
    Indication: Hodgkin's Disease

Other drugs received by patient: Radiotherapy



Possible Cytarabine side effects in male

Reported by a physician from Italy on 2012-08-09

Patient: male

Reactions: Respiratory Failure, Chills, Pancytopenia, Condition Aggravated, Pyrexia, Lung Infection Pseudomonal, Septic Shock, Oxygen Saturation Decreased

Adverse event resulted in: death

Drug(s) suspected as cause:
Alkeran
    Dosage: 234mg per day
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-02-15
    End date: 2012-02-15

Carmustine
    Dosage: 500mg per day
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-02-10
    End date: 2012-02-10

Cytarabine
    Dosage: 668mg per day
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-02-11
    End date: 2012-02-14

Etoposide
    Dosage: 167mg per day
    Indication: non-Hodgkin's Lymphoma
    Start date: 2012-02-11
    End date: 2012-02-14



Possible Cytarabine side effects in 66 year old male

Reported by a physician from France on 2012-08-07

Patient: 66 year old male, weighing 82.0 kg (180.4 pounds)

Reactions: Stenotrophomonas Infection, Coma, Device Related Infection, Pyrexia, Hypernatraemia, Loss of Consciousness, Malaise, Meningeal Disorder, Oedema Peripheral, Eye Movement Disorder, Blood Creatinine Increased, Cough, Hyperphosphataemia, Pleurisy, Pancytopenia, General Physical Health Deterioration, Aplasia, Convulsion, Nephrogenic Diabetes Insipidus, Neutropenia, Citrobacter Infection, Generalised Oedema, Hyperuricaemia, Myalgia, Weight Increased, Pleural Effusion, Crepitations, Thrombocytopenia, Jugular Vein Thrombosis, Candidiasis, Renal Failure Acute, Dyspnoea, Mucosal Inflammation, Diarrhoea, Monoparesis, Inflammation

Adverse event resulted in: death, life threatening event, hospitalization, disablity

Drug(s) suspected as cause:
Cytarabine
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2012-02-28
    End date: 2012-03-02

Etoposide
    Dosage: 400 mg/m2 daily; uid/qd
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2012-02-28
    End date: 2012-03-02

Melphalan Hydrochloride
    Dosage: 250 mg total dose
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2012-03-03

Treanda
    Dosage: 180 mg/m2 daily; 358.5 mg on day 1 + 2 of each cycle
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2012-02-27
    End date: 2012-02-28

Treanda
    Indication: non-Hodgkin's Lymphoma



Possible Cytarabine side effects in female

Reported by a physician from Netherlands on 2012-08-06

Patient: female, weighing 61.9 kg (136.2 pounds)

Reactions: Pancytopenia, Ascites

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Clofarabine
    Dosage: 17 mg at day 2, 4, 6, 8, 10, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-07-01
    End date: 2012-07-09

Cytarabine
    Dosage: unk, from day 1 to 10
    Indication: Product Used FOR Unknown Indication

Cytarabine

Idarubicin HCL
    Dosage: 17 mg at day 1, 3, 5
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-30
    End date: 2012-07-04



Possible Cytarabine side effects in 65 year old male

Reported by a physician from France on 2012-08-06

Patient: 65 year old male, weighing 74.0 kg (162.8 pounds)

Reactions: Oedema Peripheral, Pancytopenia, Blood Creatinine Increased, Generalised Oedema, Renal Failure Acute

Adverse event resulted in: life threatening event, hospitalization, disablity

Drug(s) suspected as cause:
Cytarabine
    Dosage: continuous infusion w/syringe driver 775 mg/day-day 2 to 5
    Indication: Bone Marrow Conditioning Regimen

Etoposide
    Dosage: 380 mg from day 2 to day 5
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2012-03-06

Rituximab
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2012-03-06

Treanda
    Dosage: 200 mg/kg daily; day 1 and 2 of each cycle
    Indication: Bone Marrow Conditioning Regimen
    Start date: 2012-03-05

Other drugs received by patient: Melphalan Hydrochloride



Possible Cytarabine side effects in female

Reported by a physician from Netherlands on 2012-08-03

Patient: female, weighing 61.9 kg (136.2 pounds)

Reactions: Pancytopenia, Ascites

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Clofarabine
    Dosage: 17 mg at day 2, 4, 6, 8, 10, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-07-01
    End date: 2012-07-09

Cytarabine
    Dosage: unk, from day 1 to 10
    Indication: Product Used FOR Unknown Indication

Cytarabine

Idarubicin HCL
    Dosage: 17 mg at day 1, 3, 5
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-06-30
    End date: 2012-07-04



Possible Cytarabine side effects in female

Reported by a physician from Netherlands on 2012-08-02

Patient: female, weighing 73.0 kg (160.6 pounds)

Reactions: Bronchopulmonary Aspergillosis, Respiratory Failure, Pancytopenia, Neutropenia, Thrombocytopenia, Cerebral Haemorrhage, Influenza

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Amsacrine
    Dosage: 225 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-10

Clofarabine
    Dosage: 19 mg, qd; day 1 to 5; cycles i and ii
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-07

Cytarabine
    Dosage: 1900 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-07

Other drugs received by patient: Amphotericin B; Meropenem; Vancomycin; Voriconazole



Possible Cytarabine side effects in 41 year old female

Reported by a health professional (non-physician/pharmacist) from Turkey on 2012-07-31

Patient: 41 year old female

Reactions: Uterine Leiomyoma, Tachycardia, Pancytopenia, Pallor, Uterine Haemorrhage

Drug(s) suspected as cause:
Cytarabine
    Dosage: 100 mg/m^2, unknown, unknown 2 q/m^2, unknown
    Indication: Acute Myeloid Leukaemia

Daunorubicin HCL
    Dosage: 45 mg/m^2, unknown, unknown
    Indication: Acute Myeloid Leukaemia

Other drugs received by patient: Desogestrel and Ethinyl Estradiol



Possible Cytarabine side effects in female

Reported by a physician from Netherlands on 2012-07-30

Patient: female, weighing 61.9 kg (136.2 pounds)

Reactions: Pancytopenia, Ascites

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Clofarabine
    Dosage: 17 mg at day 2, 4, 6, 8, 10, unk
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-07-01

Cytarabine
    Dosage: unk, from day 1 to 10
    Indication: Product Used FOR Unknown Indication

Cytarabine

Idarubicin HCL
    Dosage: 17 mg at day 1, 3, 5
    Indication: Product Used FOR Unknown Indication
    Start date: 2012-06-30



Possible Cytarabine side effects in female

Reported by a physician from Netherlands on 2012-07-27

Patient: female, weighing 73.0 kg (160.6 pounds)

Reactions: Bronchopulmonary Aspergillosis, Respiratory Failure, Pancytopenia, Thrombocytopenia, Cerebral Haemorrhage, Influenza

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Amsacrine
    Dosage: 225 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-10

Clofarabine
    Dosage: 19 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-07

Cytarabine
    Dosage: 1900 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-07

Other drugs received by patient: Meropenem; Vancomycin; Amphotericin B



Possible Cytarabine side effects in 50 year old female

Reported by a individual with unspecified qualification from Canada on 2012-07-26

Patient: 50 year old female

Reactions: Haemoptysis, Haemorrhage, Refractoriness To Platelet Transfusion, Petechiae, Pancytopenia, Febrile Neutropenia, Alveolitis Allergic, Panniculitis, Colitis, Laryngospasm, Klebsiella Sepsis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 100 mg/m2, on days 1-7
    Indication: Acute Myeloid Leukaemia

Etoposide
    Dosage: 100 mg/m2, on days 1-5
    Indication: Acute Myeloid Leukaemia

Idarubicin Hydrochloride
    Dosage: 12 mg/m2, on days 1-3
    Indication: Acute Myeloid Leukaemia

Mitoxantrone Hydrochloride
    Dosage: 10 mg/m2, on days 1-5
    Indication: Acute Myeloid Leukaemia



Possible Cytarabine side effects in female

Reported by a physician from Netherlands on 2012-07-23

Patient: female, weighing 73.0 kg (160.6 pounds)

Reactions: Bronchopulmonary Aspergillosis, Respiratory Failure, Pancytopenia, Thrombocytopenia, Cerebral Haemorrhage, Influenza

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Amsacrine
    Dosage: 225 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-10

Clofarabine
    Dosage: 19 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-07

Cytarabine
    Dosage: 1900 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-07

Other drugs received by patient: Meropenem; Vancomycin; Amphotericin B



Possible Cytarabine side effects in 11 year old female

Reported by a physician from United States on 2012-07-23

Patient: 11 year old female, weighing 54.7 kg (120.3 pounds)

Reactions: Pancytopenia, Pyrexia, Caecitis, Enterocolitis Infectious

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 1000 mg/m2, cyclic
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-03-10
    End date: 2012-06-04

Cytarabine

Etoposide
    Dosage: 150 mg/m2, cyclic
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-03-10
    End date: 2012-06-04

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-03-10
    End date: 2012-06-08



Possible Cytarabine side effects in female

Reported by a physician from Netherlands on 2012-07-17

Patient: female, weighing 73.0 kg (160.6 pounds)

Reactions: Pneumonia, Respiratory Failure, Pancytopenia, Thrombocytopenia, Cerebral Haemorrhage, Influenza

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Amsacrine
    Dosage: 225 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-10
    End date: 2012-05-12

Clofarabine
    Dosage: 19 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-07
    End date: 2012-05-11

Cytarabine
    Dosage: 3800 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2012-05-07
    End date: 2012-05-12

Other drugs received by patient: Amphotericin B; Meropenem; Vancomycin



Possible Cytarabine side effects in 50 year old female

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-17

Patient: 50 year old female

Reactions: Haemoptysis, Refractoriness To Platelet Transfusion, Pancytopenia, Petechiae, Febrile Neutropenia, Pyrexia, Alveolitis Allergic, Panniculitis, Colitis, Thrombocytopenia, Klebsiella Sepsis, Laryngospasm

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 100 mg/m2, on days 1-7
    Indication: Acute Myeloid Leukaemia

Etoposide
    Dosage: 100 mg/m2, on days 1-5
    Indication: Acute Myeloid Leukaemia

Idarubicin Hydrochloride
    Dosage: 12 mg/m2, on days 1-3
    Indication: Acute Myeloid Leukaemia

Mitoxantrone Hydrochloride
    Dosage: 10 mg/m2, on days 1-5
    Indication: Acute Myeloid Leukaemia



Possible Cytarabine side effects in 50 year old female

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-06

Patient: 50 year old female

Reactions: Haemoptysis, Refractoriness To Platelet Transfusion, Petechiae, Pancytopenia, Febrile Neutropenia, Pyrexia, Alveolitis Allergic, Death, Panniculitis, Colitis, Thrombocytopenia, Laryngospasm, Klebsiella Sepsis

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 100 mg/m2 on d1-7; induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Etoposide
    Dosage: 100 mg/m2 on d1-5; 2nd induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2 on d1-3; induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Immune Globulin NOS
    Indication: Pancytopenia

Mitoxantrone
    Dosage: 10 mg/m2 on d1-5; 2nd induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Other drugs received by patient: Vercyte



Possible Cytarabine side effects in 50 year old female

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-06

Patient: 50 year old female

Reactions: Haemoptysis, Refractoriness To Platelet Transfusion, Petechiae, Febrile Neutropenia, Pancytopenia, Pyrexia, Alveolitis Allergic, Panniculitis, Colitis, Thrombocytopenia, Klebsiella Sepsis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 100 mg/m2 on d1-7; induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Etoposide
    Dosage: 100 mg/m2 on d1-5; 2nd induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2 on d1-3; induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2 on d1-5; 2nd induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Other drugs received by patient: Vercyte



Possible Cytarabine side effects in 50 year old female

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-07-06

Patient: 50 year old female

Reactions: Haemoptysis, Refractoriness To Platelet Transfusion, Pancytopenia, Petechiae, Febrile Neutropenia, Pyrexia, Alveolitis Allergic, Panniculitis, Colitis, Thrombocytopenia, Klebsiella Sepsis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 100 mg/m2 on d1-7; induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Etoposide
    Dosage: 100 mg/m2 on d1-5; 2nd induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2 on d1-3; induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2 on d1-5; 2nd induction chemotherapy
    Indication: Acute Myeloid Leukaemia

Other drugs received by patient: Vercyte



Possible Cytarabine side effects in 49 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-06

Patient: 49 year old female

Reactions: Neoplasm Malignant, Swelling, Pancytopenia, Rash, Neurological Symptom, Generalised Oedema

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Carboplatin
    Dosage: 1df=auc5 also auc4
    Indication: Peritoneal Carcinoma Metastatic

Cyclophosphamide
    Dosage: cyclophosphamide hydrate day1 also 600mg/m2
    Indication: Peritoneal Carcinoma Metastatic

Cytarabine
    Indication: Peritoneal Carcinoma Metastatic

Docetaxel
    Indication: Peritoneal Carcinoma Metastatic

Doxil
    Indication: Peritoneal Carcinoma Metastatic

Epirubicin Hydrochloride
    Dosage: day1
    Indication: Peritoneal Carcinoma Metastatic

Irinotecan HCL
    Dosage: on day 1, 15
    Indication: Peritoneal Carcinoma Metastatic

Methotrexate
    Indication: Peritoneal Carcinoma Metastatic

Mitomycin
    Dosage: inj
    Indication: Peritoneal Carcinoma Metastatic

Nedaplatin
    Dosage: also 60mg/m2,12mg/m2(days1-15),120mg/m2
    Indication: Peritoneal Carcinoma Metastatic

Paclitaxel
    Indication: Peritoneal Carcinoma Metastatic

Prednisolone
    Indication: Peritoneal Carcinoma Metastatic



Possible Cytarabine side effects in 77 year old male

Reported by a consumer/non-health professional from Japan on 2012-07-06

Patient: 77 year old male, weighing 57.0 kg (125.4 pounds)

Reactions: Sepsis, Circulatory Collapse, Febrile Neutropenia, Pancytopenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-05-28
    End date: 2010-08-19

Methotrexate
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-05-28
    End date: 2010-08-19

Oncovin
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-08-23
    End date: 2010-08-30

Pinorubin
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-08-23
    End date: 2010-08-25

Prednisolone
    Dosage: 10mg/day 28may10-19aug10,23aug10-31aug10
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-05-28
    End date: 2010-08-31

Sprycel
    Dosage: 70mg 2/1d 28jun-05jul 50mg 1/1d 06jul-22aug10 reduced 140mg to 50mg
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2010-06-28
    End date: 2010-08-22

Other drugs received by patient: Lasix; Sodium Bicarbonate; Neutrogin; Diamox; Famotidine; Pursennid



Possible Cytarabine side effects in 50 year old female

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-06-29

Patient: 50 year old female

Reactions: Mouth Haemorrhage, Haemoptysis, Acute Myeloid Leukaemia, Petechiae, Febrile Neutropenia, Pancytopenia, Pyrexia, Alveolitis Allergic, Panniculitis, Colitis, Thrombocytopenia, Laryngospasm, Klebsiella Sepsis

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 100 mg/m2, on days 1 to 7
    Indication: Acute Myeloid Leukaemia

Etoposide
    Dosage: 100 mg/m2 on days 1-5
    Indication: Acute Myeloid Leukaemia

Idarubicin HCL
    Dosage: 12 mg/m2, on days 1 and 3
    Indication: Acute Myeloid Leukaemia

Mitoxantrone
    Dosage: 10 mg/m2, unk
    Indication: Acute Myeloid Leukaemia



Possible Cytarabine side effects in male

Reported by a physician from Netherlands on 2012-06-28

Patient: male, weighing 82.0 kg (180.4 pounds)

Reactions: Rash Generalised, Hyperacusis, Angina Pectoris, Pancytopenia, Staphylococcal Sepsis, Speech Disorder, Multi-Organ Failure, Central Nervous System Haemorrhage, Transient Ischaemic Attack, Jugular Vein Thrombosis, Septic Shock

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Amsacrine
    Dosage: 220 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2011-10-31
    End date: 2011-11-02

Cytarabine
    Dosage: 1850 mg, bid
    Start date: 2011-10-28
    End date: 2011-11-02

Cytarabine
    Dosage: 360 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2011-09-23
    End date: 2011-09-29

Evoltra
    Dosage: 18 mg, unk (cycle 1)
    Indication: Acute Myeloid Leukaemia
    Start date: 2011-09-23
    End date: 2011-09-27

Evoltra
    Dosage: 18 mg, unk (cycle 2)
    Start date: 2011-10-28
    End date: 2011-11-01

Idarubicin HCL
    Dosage: 22 mg, unk
    Indication: Acute Myeloid Leukaemia
    Start date: 2011-09-23
    End date: 2011-09-25



Possible Cytarabine side effects in 49 year old female

Reported by a consumer/non-health professional from Japan on 2012-06-25

Patient: 49 year old female

Reactions: Neoplasm Malignant, Swelling, Pancytopenia, Rash, Neurological Symptom, Generalised Oedema

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Carboplatin
    Dosage: 1df=auc5 also auc4
    Indication: Peritoneal Carcinoma Metastatic

Cyclophosphamide
    Dosage: cyclophosphamide hydrate day1 also 600mg/m2
    Indication: Peritoneal Carcinoma Metastatic

Cytarabine
    Indication: Peritoneal Carcinoma Metastatic

Docetaxel
    Indication: Peritoneal Carcinoma Metastatic

Doxil
    Indication: Peritoneal Carcinoma Metastatic

Epirubicin Hydrochloride
    Dosage: day1
    Indication: Peritoneal Carcinoma Metastatic

Irinotecan HCL
    Dosage: on day 1, 15
    Indication: Peritoneal Carcinoma Metastatic

Methotrexate
    Indication: Peritoneal Carcinoma Metastatic

Mitomycin
    Dosage: inj
    Indication: Peritoneal Carcinoma Metastatic

Nedaplatin
    Dosage: also 60mg/m2,12mg/m2(days1-15),120mg/m2
    Indication: Peritoneal Carcinoma Metastatic

Paclitaxel
    Indication: Peritoneal Carcinoma Metastatic

Prednisolone
    Indication: Peritoneal Carcinoma Metastatic



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017